All News

Exec joins the organization with decades of biopharma experience.

The company announced that it is fully funded beyond clinical Phase IIb ALS results.

The injector is designed for at-home or in-clinic use.

Copp comes to the company from McKinsey & Co.

EXXUA has been approved for treatment.

The company announced new hires for its chief scientific officer, chief business officer, and other leadership roles.

Hunt joins the company from HeartBeam.

Abrysvo reportedly reduces risk of condition in baby by 57% in the first six months after birth.

The treatment is approved for conditional marketing authorization.

The device, Maverick, utilizes Raman spectroscopy for bioprocess control.

Location aims to translate research into multiple real-world treatments.

Barone is a former FDA officer.

The drug, 9MW3011, is also approved for clinical study by NMPA.

The blockbuster drug has previously been approved to treat multiple heart and diabetes-related conditions.

With treatments becoming more complex, the life sciences industry needs more professionals with specialized knowledge.

The system will be part of a NPH study.

The drug now has a new approved dosing schedule.

The agency granted the treatment with 510(k) clearance.

ResVita will use the money to develop a treatment for severe atopic dermatitis.

Move comes amid company’s shift to focusing on healthcare innovation exclusively.

Submission to focus on maintenance therapy in adults with moderately to severely active Crohn’s disease.

Appointment comes amid resignation of Marie-France Tschudin from company executive committee.

Embrace the tools that solve real problems and make life easier.

One of the most special things about Pharmaceutical Executive®, in my opinion, is when people share their stories—where they came from; how their upbringing or education or background impacted their desire to work in pharma; any personal ties to their work, such as finding new treatments in a specific disease state due to a loved one having been impacted by that same disease; and just generally sharing their passion for their work. As someone who’s worked in pharma journalism for many years, there’s something extraordinary to hear about the why for individuals.

After concerns raised by multiple supply chain participants over readiness, the agency steps back.

Results based on a 2022 global PatientView survey.

In this Q&A, Matt Smith, vice president of research site development, Slope, discusses the competition pharma companies and trial sponsors face when trying to become a sponsor of choice and build trust with sites and patients.